Clinical Trials

Accrual Status
Limit to SWOG Trials

1028 Results

    View
    Status Trial Number Title Activated Closed Accrual Phase Published
    Closed S1312 PI/II Inotuzumab + CVP for R/R CD22+ ALL 4/1/2014 8/2/2019 100%
    Closed S1320 Melanoma - Ph II Intermittent vs Continuous Dabrafenib and Trametinib BRAF Positive Melanoma 7/22/2014 7/15/2019 100%
    Closed S1416 Ph II Cisplatin +/- ABT 888 in Metastatic TNBC and/or BRCA 7/7/2016 6/15/2019 100%
    Closed S1207 Ph. III Randomized, Everolimus in high risk, hormone receptor positive, HER2 negative patients. 9/3/2013 5/1/2019 100%
    Closed S1417CD Impact of Cancer on Finances 4/15/2016 2/1/2019 100%
    Closed S1400K Lung-MAP S1400K: c-MET Positive 2/5/2018 12/21/2018 64%
    Closed S1400G Lung-MAP S1400G: HRRD - Talazoparib (BMN 673) 2/7/2017 7/23/2018 85%
    Closed S1403 Lung Ph II/III Stage IV NSCLC Afatinib+Cetuximab vs Afatinib 3/25/2015 4/23/2018 29%
    Closed S1400I Lung-MAP S1400I: Non-Match, Nivolumab + Ipilimumab 12/18/2015 4/23/2018 79%
    Closed S1507 Ph II Tram + doce with kras NSCLC + and PD 7/18/2016 3/15/2018 100%
    Closed S1314 Phase II COXEN Trial for Localized Bladder Cancer 7/9/2014 12/1/2017 100%
    Closed S0919 Phase II Idarubicin/AraC + Pravastatin for Relapsed AML 8/15/2009 9/15/2017 100%
    Closed S1216 Metastatic Prostate Cancer, Phase III ADT+TAK-700 vs. ADT+Bicalutamide 3/1/2013 7/15/2017 100%
    Closed S1011 Muscle-Invasive Bladder Ca, Std vs Ext PLND, Ph III 8/1/2011 4/15/2017 100%
    Closed S1204 Viral Screening Study 8/29/2013 2/15/2017 100%
    Closed S1400B Lung-MAP S1400B: PI3K - GDC-0032 6/15/2014 12/12/2016 57%
    Closed S1400D Lung-MAP S1400D: FGFR - AZD4547 6/15/2014 10/31/2016 81%
    Closed S1013 EGFR Skin Toxicity Validation 11/15/2011 10/1/2016 94%
    Closed S0931 Adjuvant Renal Cell, Everolimus vs Placebo, Ph III 4/1/2011 9/15/2016 100%
    Closed S1300 Rand Ph II of Crizotinib + Pem vs Pem in ALK+ NSCLC Pts Progressing Post Crizotinib 8/1/2014 9/1/2016 1%
    Scroll Table